OVARIAN CANCER and US: lancet oncology ovarian cancer detection study

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label lancet oncology ovarian cancer detection study. Show all posts
Showing posts with label lancet oncology ovarian cancer detection study. Show all posts

Sunday, January 31, 2010

Editorial: The heterogeneity of epithelial ovarian cancer. Getting it right David M. Gershenson



Editorial
The heterogeneity of epithelial ovarian cancer
Getting it right


David M. Gershenson, MD *
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
email: David M. Gershenson (DGERSHEN@mdanderson.org)

Abstract
Epithelial ovarian cancer is heterogeneous and comprises 4 major rare subtypes - mucinous, clear cell, low-grade serous, and endometrioid - all distinct from the more common high-grade serous carcinoma. Women with uncommon histotypes should be triaged to separate clinical trials.

Pathways to the diagnosis of ovarian cancer in the UK: a cohort study in primary care BJOG



Search of: ovarian cancer | Open Studies | Adult - Results by Topic - ClinicalTrials.gov



Search results for Dietary Supplement - ovarian cancer:

Acidophilus 1 study
Arginine 1 study
Calciferol 4 studies
Cholecalciferol 3 studies
Citrate 13 studies
Folate 7 studies
Folic Acid 7 studies
Folinic Acid 8 studies
Orange 1 study
Tea 1 study
Tyrosine 1 study
Vitamin B9 7 studies
Vitamin D3 3 studies

Thursday, January 28, 2010

Australian public service announcement - ovarian cancer on Youtube



Illumina to Complete Analysis of Ovarian Cancer - Sequencing - Genome Web



"The original plan was to analyze 25 ovarian and 25 gastric tumor/normal pairs by the end of 2009 using the company's Genome Analyzer, including whole-genome sequencing to at least 30-fold coverage, mRNA-seq, methylation sequencing, and chip genotyping. That timeline got delayed somewhat, and the company now expects to finish the ovarian tumors by the end of March and move into a validation phase, and then tackle the gastric cancer samples.

The delay was largely due to a longer-than-expected process of acquiring and qualifying the samples, Heath explained. For the ovarian cancer project, for example, he said the company was looking for stage I or II samples with a tumor content of at least 70 percent from non-smokers who did not have mutations in the BRCA 1 or 2 genes. He also said that the type of consent required for whole-genome sequencing is "quite a bit different from what is normally consented" and required the company, in some instances, to go back and ask for additional consent."

Women's decision-making needs related to treatment for recurrent ovarian cancer: a pilot study



"abstract:
The purpose of this pilot study was to describe the decision-making needs of women with ovarian cancer related to treatment of recurrent disease. ..... CONCLUSIONS: The findings provide some beginning direction for an inter-professional decision support approach, as well as implications for future research.

Saturday, January 23, 2010

Understanding the problem of inadequately staging of early ovarian cancer (subanalysis of ACTION trial)



CONCLUSIONS: Even in a randomised trial in which comprehensive surgical staging was strongly advised in the study protocol the majority of patients (66%) were incompletely staged. Factors relating to a lack of surgical skills attributed most to the number of incompletely staged patients, but insufficient knowledge of the tumour behaviour and routes of spread of ovarian cancer also contributed substantially to this problem. Multicentre trials recruiting patients from many institutes with small volume contribution to the study, run the risk of inadequate adherence to the study protocol.

Friday, January 22, 2010

Vermillion Emerges From Bankruptcy -- FREMONT, Calif., Jan. 22 /PRNewswire-FirstCall/ --



"This is a great day for all of our stakeholders as well as women who will benefit from OVA1,' said Gail Page, executive chair of Vermillion. 'We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease,' she added."

Cochrane Collaboration review: Antigen-specific active immunotherapy for ovarian cancer



"AUTHORS' CONCLUSIONS: We conclude that despite promising immunological responses no clinically effective antigen-specific active immunotherapy is yet available for ovarian cancer. Furthermore, the adoption of guidelines to ensure uniformity in trial conduct, response definitions and trial reporting is recommended to improve quality and comparability of immunotherapy trials."